Corbus Pharmaceuticals Holdings, Inc.CRBPEarnings & Financial Report
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel targeted therapies for rare, serious inflammatory, fibrotic and immune-mediated diseases. It primarily operates across North America and other developed markets, addressing high unmet medical needs for underserved patient populations.
CRBP Q3 FY2024 Key Financial Metrics
Revenue
$1.2M
Gross Profit
N/A
Operating Profit
$-15.5M
Net Profit
$-13.8M
Gross Margin
N/A
Operating Margin
-1304.0%
Net Margin
-1159.2%
YoY Growth
447.9%
EPS
$-1.15
Corbus Pharmaceuticals Holdings, Inc. Q3 FY2024 Financial Summary
Corbus Pharmaceuticals Holdings, Inc. reported revenue of $1.2M (up 447.9% YoY) for Q3 FY2024, with a net profit of $-13.8M (down 37.1% YoY) (-1159.2% margin).
Key Financial Metrics
| Total Revenue | $1.2M |
|---|---|
| Net Profit | $-13.8M |
| Gross Margin | N/A |
| Operating Margin | -1304.0% |
| Report Period | Q3 FY2024 |
Corbus Pharmaceuticals Holdings, Inc. Annual Revenue by Year
Corbus Pharmaceuticals Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $-1.1M).
| Year | Annual Revenue | |
|---|---|---|
| 2022 | $-1.1M | — |
Corbus Pharmaceuticals Holdings, Inc. Quarterly Revenue & Net Profit History
Corbus Pharmaceuticals Holdings, Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $1.2M | +447.9% | $-13.8M | -1159.2% |
| Q2 FY2024 | $906.0K | +290.5% | $-10.0M | -1103.4% |
| Q1 FY2024 | $-177.0K | +73.9% | $-6.9M | 3897.4% |
| Q4 FY2022 | $-641.0K | — | $-10.9M | 1697.3% |
| Q3 FY2022 | $0 | — | $-8.8M | N/A |
| Q2 FY2022 | $-490.3K | -459.1% | $-13.2M | 2702.0% |
| Q1 FY2022 | $0 | — | $-9.4M | N/A |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $-490339 | $0 | $-640954 | $-177015 | $906000 | $1.2M |
| YoY Growth | N/A | -459.1% | N/A | N/A | 73.9% | 290.5% | 447.9% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Assets | $95.7M | $82.1M | $73.8M | $66.3M | $125.7M | $152.0M | $164.2M |
| Liabilities | $34.5M | $32.6M | $31.9M | $33.3M | $28.8M | $26.4M | $13.7M |
| Equity | $61.2M | $49.5M | $41.9M | $33.0M | $97.0M | $125.5M | $150.5M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-10.6M | $-12.2M | $-7.2M | $-7.5M | $-8.0M | $-8.9M | $-13.9M |